Thalidomide is best described as a teratogenic medication that caused limb defects. Historically, it was given to pregnant women as a sedative and antiemetic, but it led to thousands of babies being born with serious congenital limb abnormalities, often during early stages of fetal limb development. This outcome showed that thalidomide can disrupt normal fetal growth, especially affecting limb formation, which is the hallmark of its teratogenic effects. In modern medical use, it’s kept under strict controls with pregnancy prevention protocols precisely because of that teratogenic risk, and it is not considered a stimulant, a vaccine, or a non-teratogenic supplement.

Body composition, especially the fat-to-muscle ratio, influences how a drug is distributed in the body. Lipophilic drugs tend to partition into fatty tissue, so having more fat relative to muscle increases the volume of distribution. This means more of the drug sits in fat stores and is released more slowly, which can alter the effective exposure of the tissues to the drug and can slow down its apparent metabolism and clearance. In contrast, choices like eye color, shoe size, or favorite cuisine don’t reflect body fat or lean mass and thus don’t impact how drugs are distributed or processed.

Cross-tolerance is when tolerance to one drug extends to another drug that acts on a similar system. Alcohol and benzodiazepines both enhance GABA-A receptor activity, producing greater inhibitory effects in the brain. When someone experiences chronic alcohol use, the brain adapts at the GABAergic system—changes in receptor function or subunit composition reduce responsiveness not just to alcohol but to other drugs that act on the same receptor, like benzodiazepines. So, the net effect is that higher doses of benzodiazepines are needed to achieve the same effect, illustrating a pharmacodynamic tolerance that spans to the other drug. This isn’t about drug levels or metabolism (pharmacokinetic tolerance), and it isn’t a lack of interaction.

Metabolism of alcohol in the liver proceeds in two steps: ethanol is first oxidized to acetaldehyde, and then acetaldehyde is oxidized to acetate. The enzyme aldehyde dehydrogenase catalyzes this second step, producing acetate as the end product. Acetate can then be used in the body to form acetyl-CoA and enter the energy-producing pathways. This is why acetate is the correct final product. Ethanol is the starting fuel, not the end product; acetaldehyde is an intermediate and is more toxic, and formate is produced in methanol metabolism, not ethanol metabolism.